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Abstract
 
We eluted peptides from class I molecules of HLA-A2.1
 
 
 
 breast adenocarcinoma and loaded
reverse phase high-performance liquid chromatography (HPLC) fractions onto dendritic
cells to prime naive CD8
 
 
 
 T cells. Fractions that supported growth of tumor-specific cyto-
toxic T lymphocytes were analyzed by nano-HPLC micro-ESI tandem mass spectrometry.
Six HLA-A2.1-binding peptides, four 9-mers (P1-P4) differing in the COOH-terminal resi-
due, and two 10-mers (P5 and P6) with an additional COOH-terminal alanine, were identi-
fied in one fraction. Peptide sequences were homologous to cyclin B1. We primed CD8
 
 
 
 T
cells from another HLA-A2.1
 
 
 
 healthy donor with synthetic peptides and generated P4-spe-
cific responses. We also detected memory T cells specific for one or more of these peptides
in patients with breast cancer and squamous cell carcinomas of the head and neck (SCCHN).
T cells from one patient, restimulated once in vitro, could kill the tumor cell line from which
the peptides were derived. Immunohistochemical analysis of tumor lines and tissue sections
showed cyclin B1 overexpression and aberrant localization in the cytoplasm instead of the nu-
cleus. Sequencing genomic DNA and cDNA corresponding to P1–P6 region showed that dif-
ferences in COOH-terminal residues were not due to either DNA mutations or errors in tran-
scription, suggesting a high error rate in translation of cyclin B1 protein in tumors.
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Introduction
 
For tumor-specific immunotherapy to be successful, tu-
mor antigens must be identified that are effective in induc-
ing strong immune responses in the host. A number of
methods have been described to identify tumor antigens,
including transfection of recombinant tumor cDNA li-
braries and HLA molecules into target cells (“genetic ap-
proach”) (1, 2), elution of peptides from the binding cleft
of tumor HLA molecules (“peptide-elution approach”) (3,
4), deduction of peptide sequences from known onco-
genes or tumor-associated proteins using known HLA-
anchor motifs (“reverse immunology approach”) (5, 6), and
more recently, serological analysis of recombinant tumor
cDNA expression libraries (SEREX) (7). These methods
have led to the discovery of a number of tumor antigens,
primarily in melanomas (8). These tumor antigens have
been classified into five categories: (a) cancer testis anti-
gens, such as MAGE (9, 10), BAGE (11), GAGE (12), and
more recently, NY-ESO-1 (13); (b) differentiation anti-
gens, such as gp100 (14), Melan-A/Mart-1 (2, 15), and
tyrosinase (1); (c) mutated antigens, such as cdk4 (16),
 
 
 
-catenin (17), and cdc27 (18); (d) overexpressed and/or
ubiquitous antigens, such as PRAME (19), and p53 (20),
and (e) viral antigens, such as human papillomavirus
(HPV) (21) and EBV (22). Very few tumor-specific anti-
gens have been identified in epithelial tumors, the best
known of which are CEA (23), PSA (24), Her-2/Neu
(25), and MUC1 (26).
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Cyclin B1 as a Tumor Antigen
 
We recently described a novel method for tumor antigen
discovery whereby we primed naive CD8
 
 
 
 T cells from
healthy donors to in vitro generated dendritic cells (DCs)
 
*
 
loaded with peptides eluted from HLA class I molecules of a
breast cancer cell line (27). We identified several fractions
that supported growth of tumor-specific CTLs, suggesting
that these fractions contained peptides that could potentially
be tumor antigens. In this paper we report that one of these
fractions contained peptides derived from cyclin B1, a cell
cycle checkpoint protein that regulates the transition from
G2 to M phase (28). Staining of the tumor cell line with
anti-cyclin B1 antibody revealed that this protein was
greatly overexpressed and found mostly in the cytoplasm
rather than in its normal location, the nucleus. We were
able to prime naive CD8
 
 
 
 T cells from another healthy do-
nor using synthetic peptides and detect T cell responses to
one of the peptides using the IFN-
 
 
 
 enzyme-linked immu-
nospot (ELISPOT) assay. We also detected secondary T cell
responses to one or more of these peptides in breast cancer
patients and patients with squamous cell carcinomas of the
head and neck (SCCHN). Where we were able to evaluate,
these T cell responses correlated with the overexpression of
cyclin B1 protein in the patients’ tumors. In the fresh tumor
samples, like in the cell lines, the overexpressed protein was
found predominantly in the cytoplasm instead of the nu-
cleus. We propose that this aberrant overexpression of cy-
clin B1 in the cytoplasm leads to overabundance of cyclin
B1–derived peptides in tumor HLA class I molecules,
which can then be recognized by T cells as tumor antigens.
 
Materials and Methods
 
Cells and Tumor Cell Lines
 
MS-A2 is an HLA-A
 
*
 
0201 transfected tumor cell line derived
from a breast adenocarcinoma cell line MS, characterized in our
laboratory (27, 29). MS-A2/CD80 is the MS-A2 cell line retro-
virally transduced with the CD80 gene obtained from Corixa
Corporation. The lung tumor cell line, 201T, was obtained from
Dr. Jill Siegfried, University of Pittsburgh School of Medicine.
The head and neck tumor cell line, PCI-13, was also established
by us (30). T cells, DCs, and macrophages were derived from the
peripheral blood of HLA-A
 
*
 
0201
 
 
 
 healthy donors and cancer pa-
tients under an Institutional Review Board approved protocol
and with signed informed consent.
 
Peptide Synthesis
 
All peptides used in this study were synthesized with F-moc
chemistry using the 432A Synergy Peptide Synthesizer (Applied
Biosystems). Peptides were purified by reverse phase (RP)-HPLC
to greater than 85% purity, dissolved in DMSO, and frozen until
further use.
 
Antibodies
 
MA2.1, a mouse anti–human HLA-A2.1 antibody, was pro-
duced by the MA2.1 hybridoma; W6/32, a mouse anti–human
MHC class I antibody, was produced by the W6/32 hybridoma;
both were obtained from the American Type Culture Collection.
GNS-1, a mouse anti–human cyclin B1 antibody, was purchased
from BD PharMingen.
 
Mass Spectrometry Data Acquisition
 
Active first-dimension HPLC fractions were screened for pep-
tide content on a home-built Fourier transform mass spectrome-
ter (FTMS), equipped with a nano-flow high performance liquid
chromatography micro-electrospray ionization (nano-HPLC mi-
cro-ESI) interface (31). Nano-HPLC columns were constructed
from 50 
 
 
 
m internal diameter fused silica capillaries and packed
with an 8-cm bed length of 5-
 
 
 
m diameter reversed phase beads.
An integrated microESI emitter tip (
 
 
 
2 
 
 
 
m diameter) was lo-
cated a few mm from the column bed. Typically, 
 
 
 
0.75 
 
 
 
l (cor-
responding to 
 
 
 
2.3 
 
 
 
 10
 
8
 
 cell equivalents or 
 
 
 
1.5%) of an ac-
tive, first-dimension HPLC fraction was loaded onto a column
and eluted directly into the mass spectrometer with a linear, 17-
min gradient of 0–70% acetonitrile in 0.1% acetic acid. Full scan
mass spectra, over a mass-to-charge (
 
m/z
 
) range 300 
 
 
 
 
 
m/z
 
 
 
 
 
2500, were acquired at a rate of 
 
 
 
1 scan/second.
 
Mass Spectrometry/Mass Spectrometry Data Acquisition
 
Mass spectrometry/mass spectrometry (MS/MS) data were ac-
quired on a Finnigan LCQ quadrupole ion trap mass spectrome-
ter (Finnigan Corp.), equipped with a nano-HPLC micro-ESI
source as described above. Typically, 
 
 
 
1.5 
 
 
 
l (corresponding to
 
 
 
4.5 
 
 
 
 10
 
8
 
 cell equivalents or 
 
 
 
3%) of an active, first-dimension
HPLC fraction was loaded onto a column eluted directly into
the mass spectrometer with a linear, 30 min gradient of
0–30% acetonitrile in 0.1% acetic acid. Data-dependent spectral
acquisition (32) was performed as follows: A full scan mass spec-
trum (MS) was acquired over the range 300 
 
 
 
 
 
m/z
 
 
 
 
 
 2,000. The
instrument control computer then selected the top five most
abundant ion species in the MS scan for subsequent MS/MS anal-
ysis over the next five scans. After acquiring MS/MS data on a
particular ion species, its corresponding 
 
m/z
 
 value was excluded
from consideration by the instrument control computer for a pe-
riod equal to the observed chromatographic peak width (
 
 
 
1.5
min for the data herein). This data acquisition procedure mini-
mized redundancy and allowed MS/MS analysis on peptide spe-
cies whose abundances spanned a wide dynamic range. After ac-
quisition, tandem mass spectral data were searched using
SEQUEST (33), an algorithm that matches uninterpreted MS/
MS spectra to theoretical spectra for peptides generated from
user-specified databases. All data herein were searched against
nonredundant (nr) protein databases compiled at the National
Center for Biotechnology Information (NCBI). In addition,
manual (e.g., de novo) interpretation of MS/MS spectra was per-
formed. Peptide sequence information obtained in this manner
was compared with sequences in the nr (nonredundant) protein
database using the MS-TAG algorithm (34). Candidate peptide
sequences were subsequently confirmed by comparison of their
MS/MS spectra acquired for synthetic analogs.
 
HLA Class I Stabilization Assays
 
Peptide-induced stabilization of HLA-A2.1 molecules on T2
cells was done as described previously (35). 2 
 
 
 
 10
 
5
 
 T2 cells were
incubated with 20 
 
 
 
g/ml of the indicated synthetic peptides in 3
 
 
 
g/ml human B
 
2
 
m (Calbiochem) for 18–20 h at room tempera-
ture. The cells were then stained with the HLA-A2.1–specific
antibody, MA2.1, for 45 min, washed with FACS
 
®
 
 buffer (PBS,
5% FBS, and 0.01% sodium azide), and stained with a secondary
 
*
 
Abbreviations used in this paper:
 
 DC, dendritic cell; ELISPOT, enzyme-
linked immunospot; MS, mass spectrometry; RP, reverse phase;
SCCHN, squamous cell carcinomas of the head and neck. 
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FITC-conjugated anti-IgG antibody (Biosource International).
The cells were fixed in 4% formaldehyde before flow cytometry
analysis. The negative control consisted of T2 cells without pep-
tide. The positive control consisted of T2 cells loaded with the
Flu matrix peptide, GILGFVFTL. Flow cytometric analysis was
done using a FACScan™ flow cytometer (Becton Dickinson).
Experimental results are depicted as X-Fold increase 
 
 
 
 mean flu-
orescent intensity of T2 cells loaded with peptide/mean fluores-
cent intensity of T2 cells with no peptide. An X-Fold increase of
 
 
 
1 indicates that the peptide binds to HLA-A2.1.
 
IFN-
 
 
 
 ELISPOT Assays
 
IFN-
 
 
 
 ELISPOT assays were done as described previously
(36). Briefly, nitrocellulose plates (Millipore) were coated with
the anti–IFN-
 
 
 
 capture mAb 1-D1K (MabTech) overnight at
4
 
 
 
C. For assays using DCs as APCs, DCs were loaded with 10 
 
 
 
g
of the indicated peptides for 2–6 h, and mixed with autologous T
cells at a DC/T ratio of 1:10 for 20 h at 37
 
 
 
C. For assays using
autologous PBMCs as APCs, PBMCs were irradiated at 3,000
Rads, loaded with 10 
 
 
 
g of peptides for 4 h, and mixed with au-
tologous T cells at an APC/T ratio of 1:5 for 40 h at 37
 
 
 
C. The
T cells were seeded at 3 
 
 
 
 10
 
3
 
–10
 
5
 
 cells/well. All assays were
done in serum-free AIM-V medium (GIBCO BRL). The plates
were then washed in PBS plus 0.1% Tween and stained with
anti–IFN-
 
 
 
 mAb 7-B6–1 (Mabtech) for 2 h at 37
 
 
 
C. The plates
were washed, and the avidin-peroxidase complex (Vectastain
ABC Kit; Vector Laboratories) was added to the plates for 1 h.
The plates were then developed using AEC (Sigma-Aldrich) sub-
strate, and spots were quantified microscopically with an inverted
phase-contrast microscope (Carl Zeiss, Inc.) along with a com-
puter-assisted image analysis system (KS ELISPOT). For HLA
class I blocking experiments, the W6/32 antibody was added to
the APCs for 30–45 min before incubation with T cells.
 
T Cell Cultures
 
Priming Naive CD8
 
 
 
 T Cells from a Healthy Donor to Cyclin B1
Peptides In Vitro.
 
Naive CD8
 
 
 
 T cells and in vitro generated DCs
were purified as described previously (27). 2 
 
 
 
 10
 
4
 
 DCs were
loaded overnight with 10 
 
 
 
g/well of peptide in 96-well U-bottom
plates (Falcon) and mixed with 2 
 
 
 
 10
 
5
 
 autologous naive CD8
 
 
 
 T
cells the next day in the presence of 2 ng/ml IL-1
 
  
 
(R&D Sys-
tems), 20 U/ml IL-2 (DuPont), and 10 U/ml IL-4 (Schering
Plough). Depending on growth kinetics, T cells were fed every
3–4 d with 10 U/ml IL-2 and 5 U/ml IL-4. T cells were restimu-
lated every 7–10 d using peptide-loaded autologous macrophages.
 
Stimulating CD8
 
 
 
 T Cells from Breast Cancer and SCCHN Pa-
tients with Cyclin B1 Peptides In Vitro.
 
PBMCs from cancer pa-
tients were X-irradiated at 3,000 Rads, loaded with 10 
 
 
 
g of the
indicated peptides for 2–4 h, and mixed with autologous PBMCs
in the presence of 20 U/ml IL-2 (DuPont). The T cell cultures
were fed every 3–4 d with 10 U/ml IL-2, and restimulated every
10–12 d, if necessary, using peptide-loaded autologous irradiated
PBMCs. All T cell cultures were grown in RPMI medium (ICN
Biomedicals) supplemented with 10% human AB sera (Gemini
Products), L-glutamine, and penicillin/streptomycin (Life Tech-
nologies).
 
Cytotoxicity Assays
 
Target cells were labeled with 50 
 
 
 
Ci of Na
 
2
51
 
CrO
 
4
 
 (Amer-
sham Pharmacia Biotech) for 90 min at 37
 
 
 
C. The labeled cells
were then washed three times and plated at 10
 
3
 
 cells/well in a 96-
well V-bottom plate (Costar) with various numbers of effector T
cells. In addition, a 50-fold excess of unlabeled K562 (5 
 
 
 
 10
 
4
 
)
cells was added to the wells for 30 min before the addition of T
cells to minimize the detection of lymphokine-activated killer
(LAK) activity in the assay. The plates were briefly centrifuged
and incubated for 4 h at 37
 
 
 
C. All determinations were done in
triplicate. Supernatants were harvested using a Skatron harvesting
process (Skatron Instruments) and counted on a Cobra II series
auto gamma counting system (Packard Instrument Co.). Maxi-
mum release was obtained by adding 50 
 
 
 
l of 1% Triton X-100
to the labeled target cells. Spontaneous release was obtained by
incubating the labeled cells in the absence of T cells. Percent spe-
cific lysis was calculated from the following formula: % specific
lysis 
 
 
 
 100 
 
 
 
 (experimental release 
 
 
 
 spontaneous release)/
(maximum release 
 
 
 
 spontaneous release).
 
Immunohistochemical Staining of Cyclin B1 in Tumor Cell Lines 
and in Tumor Sections
 
For tumor cell lines, the cells were left to adhere overnight on
poly-lysine charged slides (Fisher Scientific) in the presence of
RPMI plus 10% FBS (Cellgro
 
®
 
; Media Tech, Inc.). The cells
were then fixed for 15 min on ice with either 2% Triton-X or
50% Formalin/50% acetone, blocked with serum, and stained
with the anti-cyclin B1 antibody, GNS-1 (BD PharMingen).
The avidin-biotin peroxidase method was then applied according
to manufacturer’s instructions using the Vectastain ABC Elite™
staining kit (Vector Laboratories). For SCCHN sections, forma-
lin-fixed, paraffin-embedded tumor tissues were sectioned (3–5
 
 
 
m), air-dried overnight at 37
 
 
 
C, deparaffinized and dehydrated,
and stained with the anti–human cyclin B1 antibody. The avidin-
biotin peroxidase method was applied as above according to the
instructions supplied by the manufacturer (Dako).
 
PCR Amplification of the Cyclin B1 Gene Fragment
 
Genomic DNA from two tumor cell lines (PCI-13, MS-A2)
and from PBLs of two normal donors was extracted, ethanol pre-
cipitated, and first amplified with PCR primers P1 (5
 
 
 
-GTGT-
GCCCAAGAAGATGC-3
 
 
 
) and P3 (5
 
 
 
-AGTTGGTGTCCAT-
TCACCATT-3
 
 
 
) flanking the region encoding peptides P1-P6
(nucleotide region 1,056–1,085 in HeLa cyclin B1 cDNA: Gen-
Bank/EMBL/DDBJ accession number M25753) under the fol-
lowing PCR conditions: initial denaturation step for 3 min at
94
 
 
 
C, followed by 35 cycles (30 s at 94
 
 
 
C, 1 min 55 C, 30 s at
72 C, and an elongation step for 7 min at 72 C. The PCR prod-
ucts were gel purified and a second nested-PCR reaction was
performed using primers P3 (described above) and P4 (5 -AT-
GCTGCAGCTGGTTGGTGTC-3 ) to ensure that the region
of interest in the cyclin B1 gene was actually being amplified.
The PCR products were then sequenced.
Cloning of Cyclin B1 cDNA Fragment Amplified by PCR
Total cellular RNA was extracted with Trizol™ following the
manufacturer’s protocol (GIBCO BRL), and reverse-transcribed
into cDNA using the GeneAmp® RNA PCR Kit (PerkinElmer).
Total RNA from normal lung tissue was purchased from Am-
bion. PCR amplification was done using primers P1 and P3 (de-
scribed above), and the PCR products were cloned into the
pcDNA3.1/V5-His-TOPO® plasmid vector using the TA Clon-
ing® Kit (Invitrogen). Transformants were screened for inserts us-
ing PCR primers P3 and P4, and plasmids isolated from positive
clones were sequenced.
DNA Sequence Analysis
DNA sequencing was done at the University of Pittsburgh
DNA Sequencing Facility using the dideoxy-chain termination1316 Cyclin B1 as a Tumor Antigen
method (PerkinElmer) with the specific cyclin B1 oligonucle-
otides P3 and P4 as primers.
Results
Identification of Tumor-derived Peptides Stimulatory to T
Cells. Peptides were acid-extracted from immunoaffinity
purified HLA class I molecules of an HLA-A*0201 epithe-
lial tumor cell line MS-A2, fractionated by RP-HPLC, and
loaded onto DCs from a healthy donor to prime in vitro
autologous naive CD8  T cells as described previously
(27). One RP-HPLC fraction whose peptides supported
the growth of tumor-specific CTLs (27) was further ana-
lyzed by nano-HPLC micro ESI tandem mass spectrome-
try. Analysis of the resulting MS/MS data yielded six candi-
date peptide sequences that corresponded to the mass range
expected for HLA class I–associated peptides (700–1,300
D). The abundances of these candidates represented the
majority of total ion current observed in the mass range of
700–1,300 D. Candidate peptide sequences were subse-
quently confirmed by comparison of their mass spectra ac-
quired for synthetic analogs. All six peptides had related se-
quences, with four being 9 amino acids long, and two
being 10 amino acids long (Table I). The four 9-mers (P1-
P4) were identical in the first eight amino acids and differed
at the COOH terminus, where the amino acids were va-
line (P1), methionine (P2), phenylalanine (P3), and cys-
teine (P4). The two 10-mers, P5 and P6, were identical to
P2 and P3, respectively, except for an additional alanine at
the COOH terminus. When these sequences were entered
into the protein database, they were found to be homolo-
gous to a human cyclin B1 sequence derived from HeLa
cells. These sequences were also homologous to mouse and
rat cyclin B1 (Table I).
We synthesized peptides P1-P6 along with the homolo-
gous 9 and 10 residue HeLa sequences (CB9 and CB10)
from the database and tested them for their ability to bind
HLA-A2.1 using the T2 cell line and class I stabilization as-
say. As leucine and isoleucine have identical masses and are
not distinguished by low-energy MS/MS analysis, the pep-
tides were synthesized with leucines at positions 4 and 7 to
match the leucines present at these same positions in the
HeLa cyclin B1 sequence, as well as in the mouse and rat
cyclin B1 sequences. All the peptides bound to HLA-A2.1
with various affinities, as measured by increases in mean
fluorescent intensity in anti–HLA-A2.1 staining of peptide-
loaded T2 cells. The HeLa-derived cyclin B1 peptides also
bound to HLA-A2.1. Affinities of the HeLa-derived cyclin
B1 peptides were higher than that of the tumor-derived
peptides, except for P6 (Table I).
CD8  T Cells from an HLA-A*0201 Healthy Donor Can
Be Primed to Synthetic Cyclin B1 Peptide P4. As the cyclin
B1 peptides were derived from a first dimension HPLC
fraction that primed tumor-specific CTLs from an HLA-
A2.1  donor, we sought to determine whether these pep-
tides were indeed responsible for the immunostimulatory
activity. We used naive CD8  T cells from another healthy
HLA-A2.1  donor and autologous DCs loaded with the
individual synthetic peptides (P1–P6). No T cell responses
were detected against the peptides in the absence of in vitro
stimulation in either this donor or another HLA-A2.1  do-
nor (data not shown). However, after four rounds of stimu-
lation, we detected antigen-specific IFN-   secretion by
CD8  T cells in response to P4, and not to other peptides
(P1, P2, P5, P6) or peptide HIV-POL (ILKEPGSHV) that
is known to bind HLA-A2.1 and served here as the nega-
tive control (Fig. 1). We were able to block the T cell re-
sponse to P4 using the anti–class I antibody W6/32, show-
ing that the P4-specific responses were HLA class I
restricted. These in vitro primed T cells that specifically
recognized P4-loaded DCs were unable to kill the original
tumor from which the peptides were derived (data not
shown). This was not unexpected considering that these T
cells were primed with high concentrations of peptide (50
 M), and are thus expected to be of low affinity and inca-
pable of recognizing the comparatively lower levels of the
same HLA-peptide complexes on the tumor.
HLA Class I–restricted Memory T Cell Responses against
Cyclin B1 Peptides in HLA-A*0201 Breast Cancer Patients.
We tested PBMCs from six breast cancer patients who had
undergone surgery but had not yet started chemotherapy,
for their ability to recognize the cyclin B1 peptides in an
IFN-  ELISPOT assay. Four out of the six HLA-A2 
breast cancer patients tested exhibited secondary responses
against one or more of the cyclin B1 peptides (Fig. 2). Pa-
Table I. Cyclin B1 Sequences Derived from the Tumor and 
Database Bind to HLA-A2.1 
Sequencea
HLA-A2.1
bindingb
Cyclin B1 peptides from the tumor
P1 AGYLMELCV 1.60
P2 AGYLMELCM 1.48
P3 AGYLMELCF 1.42
P4 AGYLMELCC 1.61
P5 AGYLMELCMA 1.58
P6 AGYLMELCFA 2.08
Cyclin B1 peptides from the database
Human cyclin B1 (CB9) AKYLMELTM 2.28
Human cyclin B1 (CB10) AKYLMELTML 2.25
Mouse cyclin B1 AKYLMELSML  
Rat cyclin B1 AKYLMELSML  
aTumor-derived peptides were sequenced by electrospray ionization
tandem mass spectrometry, yielding six peptides (P1–P6) having high
homology to human HeLa cyclin B1 (GenBank/EMBL/DDBJ acces-
sion number: P14635), as well as mouse (GenBank/EMBL/DDBJ ac-
cession number: P24860) and rat cyclin B1 (GenBank/EMBL/DDBJ
accession number: P30277).
bX-Fold increase   (mean fluorescent intensity of T2 cells loaded with
peptide/mean fluorescent intensity of T2 cells with no peptide). An
X-Fold increase of  1 indicates that the peptide binds to HLA-A2.1.
The positive control consisted of T2 cells loaded with the Flu matrix
peptide (GILGFVFTL), which had an X-Fold increase of 2.2.1317 Kao et al.
tient A exhibited strong HLA class I–restricted secondary T
cell responses to three of the three peptides tested, P4,
CB9, and CB10, after only one in vitro stimulation. There
was no recognition of the HIV-POL control peptide. Pa-
tient B appeared to have a weak secondary response to one
of the three peptides tested, P1, and only after two in vitro
stimulations. This patient was later found to be HLA-
A*0206, suggesting that, if the anti-P1 response is real, P1
may also bind to HLA-A*0206.
Most interestingly, we detected secondary responses in
the absence of any in vitro stimulation. Patient C showed
peptide-specific HLA class I–restricted T cell responses to
two of two peptides tested, P4 and CB9. Patient D showed
strong HLA class I–restricted T cell response to P4 and
lower responses against both the HIV-POL peptide and
CB9. However, only CB9 response was blocked by the
anti-MHC class I antibody, confirming antigen specificity.
Patients E and F did not respond to either of the two pep-
tides tested, P4 and CB9. We also did not detect responses
to any of the peptides in an HLA-A*0201 negative patient
(data not shown).
HLA Class I–restricted Memory T Cell Responses to Cyclin
B1 Peptides in HLA-A*0201 SCCHN Patients. We also
examined PBMCs from five HLA-A*0201 SCCHN pa-
tients for their ability to respond to the cyclin B1 peptides
in an IFN-  ELISPOT assay. These patients were chosen
for having either stable disease or being in long term remis-
sion. We detected HLA class I–restricted T cell responses
to one or more of the cyclin B1 peptides in four of the
five patients tested (Fig. 3). Patient A exhibited HLA class
I–restricted T cell responses to five of eight peptides, after
only one in vitro stimulation. For two of these peptides, P4
and CB9, we also detected peptide-specific T cells in the
absence of any in vitro stimulation (data not shown).
Patient B exhibited HLA class I-restricted T cell re-
sponses to three of the five peptides (P3, P4, CB9), and not
to the other two (P1, P2). Patient C showed heightened T
cell responses to all five peptides tested, but only responses
against P2 and CB10 could be blocked with anti-class I an-
tibody. Patient D had the same heightened T cell response
that appeared specific for three of the six peptides tested,
P4, P5, and CB9. The fifth SCCHN patient failed to show
a detectable response to any of the peptides even after three
in vitro stimulations (data not shown).
T Cells from a SCCHN Patient Can Lyse the Tumor from
Which the Peptides Were Derived. Because T cells from
healthy individuals primed to synthetic cyclin B1 peptides
in vitro could not kill tumor cells, we wanted to determine
whether T cells from patients that we assumed had been
primed in vivo could lyse tumor cells. We restimulated
PBLs from one SCCHN patient once in vitro with either
peptide P4 or peptide CB9 and tested the T cells for their
ability to kill the original tumor MS-A2 from which the
peptides were derived. We included in the assay the same
tumor transduced with the CD80 gene to provide “costim-
Figure 1. HLA class I–restricted T cell response of a healthy HLA-A2 
donor to cyclin B1 peptides. CD8  T cells generated in vitro by priming
to synthetic cyclin B1 peptides were used in an IFN-  ELISPOT assay
after the fourth restimulation. Number of T cells per well is indicated in
parenthesis.
Figure 2. HLA class I–restricted T cell responses to cyclin B1 peptides
in HLA-A2  breast cancer patients. PBMCs were tested for recognition
of cyclin B1 peptides after one in vitro stimulation (A, B, E, and F) or no
in vitro stimulation (C and D) in an IFN-  ELISPOT assay. Number of
T cells per well is indicated in parenthesis.1318 Cyclin B1 as a Tumor Antigen
ulation” for T cell activation (MS-A2/CD80). As shown in
Fig. 4 A, T cells restimulated once with P4 were able to
lyse the MS-A2/CD80 tumor and to a lesser extent, MS-
A2 tumor, but not the HLA-A2  target MS or K562 that
was a control target for LAK activity. Similarly, in Fig. 4 B,
T cells restimulated with CB9 peptide were able to lyse the
MS-A2 /CD80  tumor and not the other targets.
Cyclin B1 Protein Is Overexpressed in Epithelial Tumor Cell
Lines. To understand the reason why cyclin B1 peptides
would elicit T cell responses in cancer patients, we exam-
ined by immunohistochemistry the cyclin B1 expression in
the original tumor cell line MS-A2 from where they were
first isolated and identified (Fig. 5, A and B). There was in-
tense staining of cyclin B1 protein in the tumor cells, pre-
dominantly found in the cytoplasm. Fig. 5, C and D, depict
similar intense cytoplasmic staining of cyclin B1 in a human
lung adenocarcinoma cell line 201T. No cyclin B1 staining
was observed in normal cells, represented by primary cul-
tures of human airway bronchoepithelial cells (Fig. 5 E).
Cyclin B1 Protein Is Also Overexpressed in SCCHN. To
rule out that the intense staining of cyclin B1 observed in
the tumor cell lines might be a result of a prolonged in
vitro culture, we examined a tumor cell line as well as tu-
mor tissue sections obtained from the SCCHN patients
whom we had analyzed for cyclin B1–specific T cell re-
sponses. Fig. 6, A and B, shows intense cytoplasmic stain-
ing of cyclin B1 in the tumor cell line PCI-13, derived
from the tumor of patient A in Fig. 3. Very high expression
of cyclin B1 in the cell line correlates with strong cyclin
B1–specific T cell responses observed in this patient. In-
tense cytoplasmic cyclin B1 staining was also observed in
the tumor tissue samples (Fig. 6, C and D; E and F) of two
other patients who exhibited cyclin B1-specific T cell re-
sponses (patients C and D, respectively; Fig. 3). No cyclin
B1 staining was detected in the normal mucosa surround-
ing the tumor. The tumor seen in Fig. 6, G and H, showed
weak and diffuse cyclin B1 staining that was not convinc-
ingly positive. Patient B from whom the tumor was ob-
tained did have cyclin B1–specific T cell responses (Fig. 3).
Figure 3. HLA class I–restricted T cell responses to cy-
clin B1 peptides in HLA-A2.1  SCCHN patients. PBMCs
were tested for recognition of cyclin B1 peptides after one
(A) or two in vitro stimulations (B–D) in an IFN- 
ELISPOT assay.
Figure 4. T cells from an HLA-A2.1  SCCHN patient restimulated to
cyclin B1 peptides in vitro are able to kill the original tumor. T cells were
restimulated with P4 (A), and CB9 (B) for 5 d and tested in a CTL assay.1319 Kao et al.
The same weak staining was seen in the tumor shown in
Fig. 6, I and J, derived from a patient who did not exhibit
any HLA class I–restricted T cell responses against the cy-
clin B1 peptides (data not shown).
Differences in the COOH Terminus of the Cyclin B1 Peptides
Are Not the Result of DNA or RNA Mutations. As cyclin
B1 peptides P1-P6 that we isolated from MS-A2 tumor
class I molecules differed from the HeLa sequence in the
second and eighth amino acid and from each other in the
COOH-terminal residues, we set out to examine if these
differences were a result of mutations in the MS-A2 cells
DNA or RNA. We sequenced the area in the genomic
DNA corresponding to the region encoding the peptides.
As the only human cyclin B1 sequence available in the da-
tabase was from HeLa cells, we also sequenced the same re-
gion of genomic DNA from two normal donors, as well as
from the SCCHN cell line PCI-13. The sequences were all
identical in the region of interest (Table II), ruling out mu-
tations at the DNA level as the cause for generation of
these differences in the cyclin B1 peptides. We next exam-
ined the RNA by cloning and sequencing the correspond-
ing cyclin B1 cDNA from normal lung tissue and MS tu-
mor. Most of the MS sequences were identical, except for a
thymine to adenine substitution in clone MS6.1, that
would render an amino acid change from Glutamic acid
(E) to Aspartic acid (D) (Table II). This change, however,
does not contribute to the sequences of P1–P6. The other
sequences in the region of interest were identical, ruling
out mutations at the RNA level as the cause for the gener-
ation of multiple cyclin B1 peptides.
Discussion
In this study, we report the identification of cyclin B1 as
a shared epithelial tumor antigen. We used our recently
described approach of tumor antigen discovery that relies
on DCs as APCs to prime naive CD8  T cells against tu-
mor-derived peptides (27). Although a variety of ap-
proaches have been used to identify HLA class I–restricted
tumor antigens, most depended on the availability of tu-
mor-specific T cell lines or clones derived from cancer pa-
tients. Our approach employed T cells from healthy do-
nors and explored the full repertoire of anti-tumor
responses that could be generated in healthy, immuno-
competent individuals to tumor antigens presented by
professional APCs.
Figure 5. Cyclin B1 protein is overexpressed in epithelial tu-
mor cells. (A) MS-A2 cells, original magnification,  20. (B)
MS-A2 cells, original magnification,  40. (C) 201T cells, origi-
nal magnification,  20. (D) 201T cells, original magnification,
 40. (E) Human airway bronchoepithelial cells, original magni-
fication,  20.1320 Cyclin B1 as a Tumor Antigen
Cyclin B1 is an important molecule involved in the tran-
sition from G2 to M phase of the cell cycle (28). It associ-
ates with the active form of the cdc2 (cdk1) kinase in the
cytoplasm, and translocates into the nucleus where it ini-
tiates chromosome condensation, destruction of the nu-
clear membrane, and assembly of the mitotic spindle. It
then rapidly gets ubiquitinated and targeted to the protea-
some for degradation (37). Anaphase is then initiated and
the cell progresses to complete the cell cycle. Cyclin B1 is
expressed only at certain points of the cell cycle, starting
with the gradual accumulation of the protein at G1, to its
peak at G2 where it acquires the threshold needed to ini-
tiate mitosis. Overexpression of cyclin B1, detected by im-
munochemistry, has been reported in a variety of tumors,
i.e., breast, colon, prostate, oral, esophageal, and non-small
cell lung cancers (38–43). We detected overexpression of
cyclin B1 in a panel of SCCHN that showed intense cyclin
B1 staining in the tumor cells and not in the surrounding
mucosa. This was also observed in adenocarcinomas of the
lung and breast (data not shown). The overexpressed pro-
tein was found predominantly in the cytoplasm, which is
different from the nuclear localization in normal dividing
cells. Cyclin B1 overexpression in tumors correlated with
the presence of cyclin B1–specific memory T cell responses
in their PBLs, suggesting that T cells in these SCCHN pa-
tients had been primed in vivo to cyclin B1 derived from
their tumors. We hypothesize that the overexpression of
cyclin B1 in the cytoplasm in these tumors and its degrada-
tion in the proteasome increases dramatically HLA class
I-cyclin B1 peptide complexes on the tumor cell surface
making them tumor-specific targets for T cells. It would be
interesting to examine in a larger number of patients if cy-
clin B1 overexpression in SCCHN tumors and the pres-
ence of cyclin B1-specific T cell responses might correlate
with a better prognosis and increased survival.
As these cyclin B1 peptides were originally isolated from
a fraction that supported the growth of peptide-specific
CTLs that lysed the original tumor cells (27), we were sur-
prised that the synthetic peptide-primed T cells from a dif-
ferent HLA-A2  healthy donor were unable to recognize
and kill the same tumor (data not shown). We believe that
this discrepancy between T cells recognizing peptide-
loaded targets versus tumor probably lies in the compara-
tively lower density of HLA-cyclin B1 peptide complexes
on the tumor, being below the threshold necessary for rec-
ognition by the low-affinity T cells generated on synthetic
peptides in vitro. However, we expanded cyclin B1 pep-
tide-specific T cell lines from a SCCHN patient’s T cells
that had been primed in vivo and showed that these T cells
were capable of lysing the original tumor cells, especially if
the costimulatory molecule CD80 was present on the tar-
get cell. Having been primed in vivo to physiological con-
centrations of antigen that we were not able to mimic in
vitro, these T cells from a cancer patient were better at rec-
ognizing the tumor cells compared with in vitro primed T
cells from a healthy donor.
The precise mechanism that is responsible for the small
amino acid differences we see between the peptides we iso-
lated from an HPLC fraction and the sequence found from
the database has not been elucidated. One possibility we
considered was the polymorphism in human cyclin B1
genes, similar to what has been reported for rat cyclin B1
Figure 6. Cyclin B1 protein is overexpressed in SCCHN. A and B,
SCCHN cell Line PCI-13. C–J, SCCHN tumor sections. A, C, E, G,
and I, original magnification,  10. B, D, F, H, and J, original magnifica-
tion,  20.1321 Kao et al.
(44). Very little work has been done on human cyclin B1
genes. Only one has been cloned and sequenced from the
HeLa cell line and nothing is known about the degree of
polymorphism of cyclin B1 genes in that line. We have se-
quenced from normal and tumor cells the portion of the
cyclin B1 gene that contains the region encoding the pep-
tides. We observed differences in several nucleotides but all
were outside the region of interest (data not shown). No
differences were found in the specific region that encoded
the peptides, ruling out changes at the gene level as the
cause for the multiple related cyclin B1 peptides. We also
did not detect any differences at the mRNA level, suggest-
ing that the changes were most likely occurring at the pro-
tein level. A recent study has suggested that up to 30% of
proteins in a cell are mistranslated or misfolded giving rise
to defective ribosomal products (DRIPs), that are quickly
directed to the proteasome for degradation (45). This pro-
cess may even be exaggerated in transformed cells. Inas-
much as cyclin B1 also uses the ubiquitin-proteasome sys-
tem for degradation (37), we propose that the cyclin B1
peptides that we identified were derived from overex-
pressed and mistranslated cyclin B1 protein accumulating in
the cytoplasm of tumor cells.
To our knowledge, this is the first report of a human cy-
clin as a tumor antigen recognized by T cells. Although de-
regulation of the cell cycle is one of the hallmarks of hu-
man cancer, little attention has been given to exploring
cyclins as targets of an immune response, with an exception
of a brief report regarding the presence of antibody re-
sponses against cyclin B1 in hepatocellular carcinoma pa-
tients (46). Our work did not specifically set out to test cy-
clin B1 molecule as a tumor antigen either, until we found
that peptides derived from this molecule were stimulators
of a T cell response. Pathologists have previously reported
overexpression of various cyclins in certain cancers, such as
overexpression of cyclin D1 and cyclin E in breast cancer
(47), and cyclins A and B1 in melanomas (48), breast cancer
(38, 49, 50), and in oral carcinomas (41). Studies in our lab
have shown that in some tumors, G1 cyclins are found to
be more abundant while in others the G2 cyclins predomi-
nate (data not shown). Their aberrant expression may also
lead to presentation of immunogenic peptides on the sur-
face of tumors. While here we have presented data only on
peptides derived from cyclin B1, we believe that the whole
family of human cyclins could be candidate tumor antigens
provided their expression in tumor cells differs significantly
from their expression in normal cells.
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DNA
A  K  Y  L  M  E  L  T  M  L
HeLa cyclin B1 cDNA TGATGTCGAGCAACATACTTTGGCCAAATACCTGATGGAACTAACTATGTTGGAC-TATGACATGGTGCA
Normal cyclin B1 DNA (1) .......................................................-..............
Normal cyclin B1 DNA (2) .......................................................-..............
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cDNA
A  K  Y  L  M  E  L  T  M  L  
Normal cyclin B1 cDNA TGATGTCGAGCAACATACTTTGGCCAAATACCTGATGGAACTAACTATGTTGGACTATGACATGGTGCA
HeLa cyclin B1 cDNA .....................................................................
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MS6.3-cDNA .....................A...............................................
MS6.4-cDNA .....................A...............................................
MS6.5-cDNA .....................................................................
MS6.6-cDNA .-...................A...............................................
MS6.7-cDNA .....................N...............................................
MS6.9-cDNA .....................................................................
MS6.10-cDNA .....................A...............................................
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